Follow‐Up Study of Percutaneous Intramyocardial Septal Radiofrequency Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy With HFpEF
Echocardiography · 2024-11 · 41 (11)
DOI: 10.1111/echo.15930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Echocardiography, online erschienen am 05.11.2024. Verfasst von Chang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Research-related joint construction project of Henan Province.
Abstract (Originalsprache)
Background
The study aimed to evaluate the changes of left ventricular diastolic function and the improvement of clinical symptoms in hypertrophic cardiomyopathy (HCM) patients with heart failure with preserved ejection fraction (HFpEF) after percutaneous intramyocardial septal radiofrequency ablation (PIMSRA).
Methods
This study enrolled 31 adult HCM patients with HFpEF who underwent PIMSRA treatment. Electrocardiogram, imaging, and blood biochemical examinations were performed on these patients during a 6‐month follow‐up.
Results
Compared with the baseline, at 6 months after PIMSRA, patients showed significant reductions in peak left ventricular outflow tract pressure gradients (resting gradient: from a mean of 83.24 to 23.40 mmHg, p < 0.001; postexercise gradient: from a mean of 109.70 to 33.39 mmHg, p < 0.001). The interventricular septal thickness reduced from a mean of 22.90 to 17.48 mm, p < 0.001. The E/e’ decreased from a median of 18.67 to 11.54, p < 0.001. The 6‐minute walk distance (6MWD) increased from a mean of 359.03 to 435.81 m, p < 0.001. The Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OS) increased from a mean of 57.57 to 71.93, p < 0.001. The number of HFpEF patients diagnosed according to the European Society of Cardiology's Heart Failure Association HFA‐PEFF score decreased from 31 to 23. None of the patients had new‐onset bundle branch block or complete heart block after PIMSRA.
Conclusion
PIMSRA is a safe and effective treatment. It can improve left ventricular diastolic function and quality of life in HCM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Cardiology, Henan Hypertrophic Cardiomyopathy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Zhengyang Han, Ruifang Zhang
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Research-related joint construction project of Henan Province
Zitieren
APA
Wang, C., Guo, W., Duan, H., Qin, J., Wang, F., He, T., Gao, L., Han, Z., Zhang, R., & Wu, L. (2024). Follow‐Up Study of Percutaneous Intramyocardial Septal Radiofrequency Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy With HFpEF. Echocardiography, 41(11). https://doi.org/10.1111/echo.15930
Vancouver
Wang C, Guo W, Duan H, Qin J, Wang F, He T, et al. Follow‐Up Study of Percutaneous Intramyocardial Septal Radiofrequency Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy With HFpEF. Echocardiography. 2024;41(11). doi:10.1111/echo.15930
BibTeX
@article{Wang2024,
author = {Wang, Chang and Guo, Weitao and Duan, Huican and Qin, Junchang and Wang, Fangming and He, Tianyu and Gao, Lu and Han, Zhengyang and Zhang, Ruifang and Wu, Lina},
title = {Follow‐Up Study of Percutaneous Intramyocardial Septal Radiofrequency Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy With HFpEF},
journal = {Echocardiography},
year = {2024},
volume = {41},
number = {11},
doi = {10.1111/echo.15930}
}
EUVIMED